37 results on '"Kaitu'u-Lino, Tu'uhevaha"'
Search Results
2. Circulating Activin A is elevated at 36 weeks’ gestation preceding a diagnosis of preeclampsia
3. Eplerenone: A candidate drug to mitigate long-term maternal vascular dysfunction following preeclampsia.
4. P-065. New human models of preeclampsia; offering physiologically relevant assays for the development of therapeutics to ameliorate preeclamptic vascular dysfunction
5. O-004. Circulating SIGLEC6 is deranged in preeclampsia and may be a biomarker of disease severity
6. P-009. Associations between circulating sFlt-1 and PlGF and preeclampsia with severe maternal complications, or eclampsia
7. LOX-1 expression is reduced in placenta from pregnancies complicated by preeclampsia and in hypoxic cytotrophoblast
8. Esomeprazole and sulfasalazine in combination additively reduce sFlt-1 secretion and diminish endothelial dysfunction: potential for a combination treatment for preeclampsia
9. Pravastatin as the statin of choice for reducing pre-eclampsia-associated endothelial dysfunction
10. Circulating adrenomedullin mRNA is decreased in women destined to develop term preeclampsia
11. 82. Disulfiram inhibits placental sFLT-1 secretion
12. 293. Preclinical assessment of new generation antiplatelet therapies to prevent preeclampsia
13. Disulfiram inhibits placental soluble FMS-like tyrosine kinase-1 and soluble endoglin secretion independent of the proteasome
14. 200. Clinical trial of metformin to treat preterm preeclampsia: pharmacokinetics and biomarker studies
15. 190. Combination sulfasalazine and metformin are additive in reducing placental secretion of antiangiogenic factor sFlt
16. EGFL7 gene expression is regulated by hypoxia in trophoblast and altered in the plasma of patients with early preeclampsia
17. 286. Endothelin-1 is elevated prior to the development of term preeclampsia and is exacerbated in established severe early onset preeclampsia
18. 291. MicroRNAs in maternal circulation as predictors of preeclampsia at term
19. 131. EGFR and the mitochondria; two parallel pathways regulating sFLT-1 secretion from placenta
20. 296. Loss of Placental NR4A2 may contribute to the pathogeneisis of pre-eclampsia
21. Effect of sildenafil citrate on circulating levels of sFlt-1 in preeclampsia
22. sFlt-1 and soluble endoglin concentrations in serum vs plasma in preterm preeclampsia: Are they interchangeable for biomarker studies?
23. Loss of Akt increases soluble endoglin release from endothelial cells but not placenta.
24. A wash step at collection of placental biopsies from preeclamptic pregnancies does not adversely affect levels of sFlt-1 or endoglin.
25. Characterization of protocols for primary trophoblast purification, optimized for functional investigation of sFlt-1 and soluble endoglin.
26. Peptides do not prevent cleavage of endoglin to produce soluble endoglin.
27. 131. EGFR and the mitochondria; two parallel pathways regulating sFLT-1 secretion from placenta.
28. 4 Epidermal growth factor receptor positively regulates sFlt1 secretion.
29. [273-POS]: Sulfasalazine reduces the toxins of preeclampsia soluble Flt1 and soluble endoglin and quenches endothelial dysfunction in primary human tissues: A novel potential therapeutic.
30. [44-OR]: Statins reduce soluble Flt1, and quench endothelial dysfunction in primary human tissues, but increase soluble endoglin release.
31. 43 New generation antiplatelet therapies to prevent preeclampsia: Endothelial dysfunction, anti-angiogenic factors.
32. [6-OR]: Proton pump inhibitors for treatment of preeclampsia.
33. [261-POS]: Heme oxygenase-1 is not reduced in pre-eclampsia and does not regulate sFlt-1 or soluble endoglin production.
34. [28-OR]: The newly described primate and placental specific sFlt1 isoform – e15a is biologically active and antagonises VEGF.
35. Loss of Akt increases soluble endoglin release from endothelial cells but not placenta.
36. A wash step at collection of placental biopsies from preeclamptic pregnancies does not adversely affect levels of sFlt-1 or endoglin.
37. Characterization of protocols for primary trophoblast purification, optimized for functional investigation of sFlt-1 and soluble endoglin.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.